

**Title**

Drug-eluting bead chemoembolization for non-resectable Hepatocellular Carcinoma (HCC) in dogs

Purpose

Currently, there are no effective treatments for dogs with non-resectable Hepatocellular Carcinoma. Standard treatments offer only temporary palliation.

In this study researchers will investigate the efficacy and toxicity associated with intra-arterial administration of drug-eluting beads with doxorubicin administered directly into the arteries feeding the dog's tumor, a technique demonstrated to cause lower systemic doxorubicin and lower side effects vs. standard chemotherapy administration.

Eligibility

To be eligible for this study, patients must meet several criteria:

- Undergo staging to determine diagnosis of non-resectable HCC
- No medical problems which would contraindicate doxorubicin chemotherapy and general anesthesia
- Not currently being treated with chemotherapy

For more information about this study and to inquire about eligibility, please contact Dr. Weisse from the Interventional Radiology/Interventional Endoscopy Service at 646-586-1798 (chick.weisse@amcny.org).